Amgen Inc., with its diverse portfolio, demonstrates a robust presence in the pharmaceutical industry. Its strong fundamentals are underscored by a solid product lineup addressing multiple chronic diseases. While challenges in the form of high competition in the drug industry persist, the company shows promising growth potential driven by strategic partnerships and innovative research.
Amgen Inc. displays a sound financial standing with an overall fundamental score placing it favorably in the industry. Below are the individual scores across various financial metrics:
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
Analyzing historical scores helps in understanding Amgen's financial trajectory over time.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-08-05 | 3 | 5 | 5 | 4 | 1 | 2 | 1 |
| N/A | 0 | 5 | 5 | 4 | 1 | 2 | 1 |
The following table summarizes the analyst price targets for AMGN, reflecting the market's outlook and potential valuation.
| High | Low | Median | Consensus |
|---|---|---|---|
| 315 | 294 | 305 | 304.67 |
Market sentiments from analysts are quantified below, indicating the general consensus and investment sentiment towards AMGN.
| Recommendation | Number | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 21 | |
| Hold | 12 | |
| Sell | 3 | |
| Strong Sell | 0 |
Amgen Inc. stands robust with a diversified product portfolio and strong research collaborations. The company has favorable analyst sentiments driven by its continuous innovation and market expansion strategies. However, attention should be paid to its debt management and industry competition which remain as potential risks. Overall, Amgen offers appealing investment opportunities with balanced growth prospects.